Literature DB >> 19948468

Bone metastases from advanced cancers: clinical implications and treatment options.

Margaret Fitch1, Cathy Maxwell, Claire Ryan, Helen Löthman, Lawrence Drudge-Coates, Luis Costa.   

Abstract

Bone metastases are associated with considerable morbidity and can result in skeletal-related events (SREs), including pathologic fractures, the need for palliative radiotherapy, spinal cord compression, the need for surgery to bone to prevent or treat a pathologic fracture or spinal cord compression, and hypercalcemia of malignancy. Such SREs have been associated with decreases in survival and increases in healthcare costs. Skeletal morbidity and bone pain from metastases can also reduce patients' functional capacity and undermine their quality of life. Patients who develop bone metastases from advanced cancers commonly receive bisphosphonates to not only delay the onset of SREs and reduce their frequency but also provide clinically meaningful palliative effects for bone pain. Ongoing research may lead to improvements in skeletal health monitoring and management for patients with malignant bone disease.

Entities:  

Mesh:

Year:  2009        PMID: 19948468     DOI: 10.1188/09.CJON.701-710

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


  4 in total

Review 1.  Clinical efficacy of denosumab versus bisphosphonates for the prevention of bone complications: implications for nursing.

Authors:  Cynthia Campbell-Baird; Stacey Harrelson; Georgette Frey; Arun Balakumaran
Journal:  Support Care Cancer       Date:  2015-08-23       Impact factor: 3.603

2.  Improving management of patients with advanced cancer.

Authors:  Lawrence Drudge-Coates
Journal:  Patient Prefer Adherence       Date:  2010-12-02       Impact factor: 2.711

3.  Preventive medication use among persons with limited life expectancy.

Authors:  André R Maddison; Judith Fisher; Grace Johnston
Journal:  Prog Palliat Care       Date:  2011-01

4.  Urinary N telopeptide levels in predicting the anti-nociceptive responses of zoledronic acid and paclitaxel in a rat model of bone metastases.

Authors:  Qi Gui; Chengcheng Xu; Dapeng Li; Liang Zhuang; Shu Xia; Shiying Yu
Journal:  Mol Med Rep       Date:  2015-06-17       Impact factor: 2.952

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.